Annual Meeting

Degrading the mighty proteome with small molecules

Katherine A. Donovan will speak at the Discover BMB Molecular & Cellular Proteomics session
Kanika Khanna
Feb. 23, 2023

Katherine Donovan’s research path hasn’t followed a linear trajectory; she’s zig-zagged from doing basic biochemical studies to proteomics-based translational research. In her words, she is now “designing small molecules to hijack the cell’s waste disposal system and redirect it to disease-causing proteins.”

Katherine Donovan
Katherine Donovan

But Donovan’s movements have not been random, she said: “I’ve found that I gravitate toward collaborative interactions.”

During her Ph.D. at the University of Canterbury in New Zealand, Donovan studied the adaptive evolution of pyruvate kinases in E. coli. Using biochemistry and structural biology techniques, she demonstrated how mutations in the protein make the bacterium better able to tolerate low-glucose conditions.

After joining Eric Fischer’s lab at the Dana–Farber Cancer Institute in 2016, Donovan used proteomics to quantify changes in protein expression in mammalian cells when perturbed with drugs and small molecules. Her desire for collaboration motivated her to join Dana–Farber’s new Center for Protein Degradation, or CPD, in November 2018. There she built and managed the proteomics operation and developed novel technologies to advance drug discovery for different targets.

Now a lead scientist in the Fischer lab, Donovan spearheads multiple projects in proteomics as well as serving as a proteomics advisor to the CPD. Many of her projects are focused on finding degradation therapeutics for proteins involved in diseases such as cancer and Alzheimer’s.

Donovan’s favorite part about research is the community she gets to interact with daily. “People are the biggest driver in my job,” she said. “I am very lucky to have a fantastic proteomics team where everyone is super excited about science.”

Designing degradable molecules

Cells rid themselves of misfolded proteins by a process in which the proteins are ubiquitinated by the E3 ligase complex and degraded by the 26S proteasome. This pathway can be hijacked by using small-molecule degraders to recruit E3 ligases artificially to proteins linked to diseases. This process, called targeted protein degradation, or TPD, offers several advantages over conventional inhibition strategies: proteins of interest can be eliminated completely, and TPD has the potential to target a large portion of the proteome that previously was considered undruggable.

Katherine Donovan and her team at the Dana–Farber Cancer Institute recently used a chemoproteomics pipeline to identify degradable kinases by designing the degrader molecules to be as promiscuous as possible. Mutations in kinases are at the root of many human diseases, and before this project, only 7% of the human kinome was reported as degradable, making kinases attractive candidates for TPD. The team prepared a library of 91 potential kinase degrader molecules and, using proteomics, found that they degraded about 200 distinct kinases.

The researchers released their data set as a public resource to advance the field of TPD.

“Our group saw how hard it was to design these molecules and how much time, effort and money was put in,” Donovan said. “One of the ways in which we can advance the field and help other researchers is by making the data available to everyone. Science moves faster if you take a community approach.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Kanika Khanna

Kanika Khanna is the scientific program leader at the Gladstone Institute of Virology. She earned her Ph.D. at University of California, San Diego. She is passionate about science outreach and communication and likes to crochet and hike in her free time.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

From antibiotic resistance to an antibody targeting immune cells
Profile

From antibiotic resistance to an antibody targeting immune cells

Jan. 15, 2025

MOSAIC scholar Diego Pedroza got his start in chemistry, then moved to molecular biology, endocrinology and testing cancer drugs — “something that could truly make a difference.”

Ali, Falade, Usman selected for mentoring program
Member News

Ali, Falade, Usman selected for mentoring program

Jan. 13, 2025

Bashir Ali, Omolara Falade and Olalekan Usman have been selected to participate in the Scientist Mentoring & Diversity Program for Biotechnology, which pairs ethnically diverse students and early career researchers with industry mentors.

How military forensic scientists use DNA to solve mysteries
Jobs

How military forensic scientists use DNA to solve mysteries

Jan. 10, 2025

Learn how two analysts at the Armed Forces DNA Identification Laboratory use molecular biology and genetics to identify the remains of fallen troops.

A decade of teaching the Art of Science Communication
Feature

A decade of teaching the Art of Science Communication

Jan. 7, 2025

Why now, more than ever, scientists must be able to explain what they do to non-scientists.

Of genes, chromosomes and oratorios
Profile

Of genes, chromosomes and oratorios

Jan. 1, 2025

Jenny Graves has spent her life mapping genes and comparing genomes. Now she’s created a musical opus about evolution of life on this planet — bringing the same drive and experimentalism she brought to the study of marsupial chromosomes.

In memoriam: Margaret Fonda
In Memoriam

In memoriam: Margaret Fonda

Dec. 30, 2024

She taught biochemistry in a male-dominated department at a medical school and was an ASBMB member for more than 50 years.